Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Integrated Drug Discovery Process

The rapid and efficient feedback of key assay data into the iterative design and synthesis of putative drug molecules is critical to the timely delivery of drug candidates.

Whilst many large organisations strive to break down silo mentalities that segment disciplines and create barriers to team-based problem solving, Sygnature has, from day one, adopted a highly collaborative and adaptable team structure. As an integrated CRO, our teams are co-located in mixed discipline labs to facilitate effective communication and problem solving, allowing us to respond quickly to the changing needs of your research project.

Integrated Drug Discovery Process

discovery toxicology chart

Communication with customers and their authorised consultants is facilitated by our excellent informatics platform to enable transparent discussion and review or revision of project strategies. Discover more about what it means to work with Sygnature here.

Sygnature has successfully recruited many industry-experienced scientists from across the globe to enrich and augment the drug hunting knowledgebase of our founding scientists. Our scientific teams are invariably highly qualified, and each program is allocated a project leader with relevant drug discovery experience. All are keen to collaborate with customers to achieve their shared goals. Our teams’ intellectual contribution is highly valued by our customers and recognised by co-authorship in numerous published patents assigned to and held by our customer companies.

Learn more about Sygnature’s approach to the various stages of integrated drug discovery here:


Integrated Drug Discovery Process Services

Targeted Protein Degradation

Targeted protein degradation is a novel drug discovery strategy being used to develop medicines aimed at so-called ‘undruggable’ proteins. Protein degraders use a cell’s endogenous machinery – essentially, its waste disposal system – to eliminate a target protein rather than inhibit it. By taking advantage of the body’s ubiquitin proteasome system, which effectively ‘tags’ or...
View Article


Target Validation

Sygnature provides a wide range of biochemical, biophysical and cell biology methodologies for target validation, target engagement and mode of action determination.


Hit Identification

Sygnature is able to provide hit identification via screening services in a number of modes including fragment screening, virtual screening, phenotypic, high content and high throughput screening.



Sygnature is a premium provider of Hit to Lead services using its extensive expertise to assess screening hits and select the most suitable chemical series to develop into drug leads.


Lead Optimisation

Sygnature’s highly efficient Lead Optimisation services are facilitated by the rapid generation of key in-vitro data to enable our scientists to design potent molecules with drug-like properties.


Fragment Based Drug Discovery

Screening of our proprietary fragment library will provide low molecular weight hits that can be grown in a structure guided manner to deliver potent ligands with drug-like properties.


Structure-Based Drug Discovery

Whatever the origin of the hits, a structure-based approach can accelerate the enhancement of selectivity and potency during a multi-parameter lead optimisation process.


Route of Administration

Small molecule drugs are administered via many different routes, with oral (PO) being the most common due to the ease of dosing in a non-clinical setting and patient compliance. Sygnature Discovery has successfully contributed to the development of many pre-clinical development compounds and investigational medicinal products (IMPs) that have been designed for IV, PO and...
View Article


Latest News

View All

Five Arrows invests in Sygnature Discovery

Sygnature Discovery expands into early CMC development

Sygnature Discovery expands US presence with Bay…

Three of UK’s top drug discovery CROs…